Skip to content
Rebamipide
Rebamipide is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cholecystokinin receptor type A.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BX: Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) in atc
— A02BX14: Rebamipide
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dry eye syndromesD015352H04.121441—10
GastritisD005756EFO_0000217K29.7—14218
Stomach ulcerD013276K25——1315
Rheumatoid arthritisD001172EFO_0000685M06.91121—4
Sjogren's syndromeD012859EFO_0000699M35.0—1—113
DyspepsiaD004415EFO_0008533K30——11—2
Ankylosing spondylitisD013167EFO_0003898M45——11—2
OsteoarthritisD010003EFO_0002506M15-M19——11—2
Gastroesophageal refluxD005764EFO_0003948K21———1—1
EnteritisD004751K52.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Keratoconjunctivitis siccaD007638EFO_1000906—22——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD006258—1———1
Ulcerative colitisD003093EFO_0000729K51—1———1
XerostomiaD014987K11.7—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREBAMIPIDE
INNrebamipide
Description
2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid is a secondary carboxamide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1
Identifiers
PDB—
CAS-ID90098-04-7
RxCUI—
ChEMBL IDCHEMBL1697771
ChEBI ID—
PubChem CID5042
DrugBankDB11656
UNII IDLR583V32ZR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CCKAR
CCKAR
Organism
Homo sapiens
Gene name
CCKAR
Gene synonyms
CCKRA
NCBI Gene ID
886
Protein name
cholecystokinin receptor type A
Protein synonyms
CCK-A receptor, CCK-AR, CCK1-R, cholecystokinin type-A receptor, Cholecystokinin-1 receptor
Uniprot ID
P32238
Mouse ortholog
Cckar (12425)
cholecystokinin receptor type A (Q9DBV6)
Variants
Clinical Variant
No data
Financial
Rebamipide - Kubota Pharmaceutical
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,335 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
503 adverse events reported
View more details